<DOC>
	<DOCNO>NCT01178047</DOCNO>
	<brief_summary>Sleep-wake disturbance ( SWD ) frequent Parkinson 's disease ( PD ) affect quality life affect patient . Rasagiline potent , highly selective , irreversible , second-generation , monoamine oxidase type-B ( MAO-B ) inhibitor 24h dopaminergic effect . It well know dopaminergic treatment closely interact SWD . This study aim assess effect Rasagiline SWD PD patient . In randomized , double-blind , placebo control study clinical phase IV , 60 subject treat rasagiline 1mg po daily placebo 8 week . The study plan conduct 6-9 Swiss center . Questionaires use assess SWDs : sleep disturbance ( Parkinson 's Disease Sleep Scale , PDSS ) , daytime sleepiness ( Epworth Sleepiness Scale , ESS ) , fatigue ( Fatigue Severity Scale , FSS ) , apathy ( Apathy Evaluation Scale Self , AES-S ) , disability ( Sheehan scale ) QoL PD patient . - Trial medicinal product</brief_summary>
	<brief_title>Multicenter Placebo Controlled Study Assess Effect Rasagiline Sleep-wake Disturbances Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Inclusion criterion : 1 . Probable diagnosis Parkinson 's disease accord modify UK Parkinson 's Disease Society Brain Bank criteria 2 . Hoehn Yahr stage 3 offstate 3 . Age = 40 year 4 . On basis physical examination medical history , patient investigator 's opinion otherwise healthy 5 . Parkinson 's Disease Sleep Scale ( PDSS ) score = 90 . 6 . Patients stable dosage hypnotic / sedative /neuropsychiatric treatment include antiParkinsonian treatment last 4 week screen evaluation change foreseen study period . Dose adjustment make , change discontinuation drug . 7 . Subjects must understand questionnaires German , French Italian 8 . Provided sign informed consent 9 . Females childbearing potential must agree utilize highly effective contraceptive method birth control . 10 . Females child bear potential must negative pregnancy test . Exclusion criterion : 1 . Diagnosis unclear suspicion another Parkinson 's disease 2 . Patients cognitive deficit ( MMSE &lt; 26 ) 3 . Patients undergone surgery treatment PD 4 . Patients nonresponse adequate antiParkinsonian treatment 5 . History moderate severe hepatic insufficiency . 6 . Clinically relevant unstable vascular disease 7 . History drug alcohol abuse ( within past 10 year ) 8 . Patients history psychotic disorder 9 . Patients treatment resistant/recurrent major depression ( HADS =19 ) 10 . Patients unstable dosage antiParkinsonian neuropsychiatric treatment last 4 week screen evaluation . 11 . Concomitant use fluoxetine , fluvoxamine , pethidine monoamine oxidase inhibitor ( MAOI ) course study within 3 month prior screen evaluation . Patient may rescreened 3 month discontinuation mention drug . 12 . Concomitant use dextromethorphan , ephedrine pseudoephedrine course study 13 . Women pregnant lactate 14 . Participation another study 30 day prior participation study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>